Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-7706621
- Development stage
- Preclinical
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral, Intraperitoneal
01
Overview
**JNJ-7706621** is a small molecule, dual inhibitor targeting both cyclin-dependent kinases (CDKs) and Aurora kinases. It potently inhibits CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, and Aurora kinase A/B, resulting in disruption of cell cycle progression. In preclinical studies, JNJ-7706621 blocks tumor cell proliferation by causing G2/M phase arrest, endoreduplication, and apoptotic cell death, while showing reduced toxicity toward normal cells. The drug has demonstrated antitumor activity in xenograft models across multiple cancer types and can synergistically overcome resistance to radioimmunotherapy in activated B cell–like diffuse large B cell lymphoma. JNJ-7706621 has not progressed to clinical trials[1][3][5][7].
- Other names
- Aurora Kinase Inhibitor II4-(4'-Benzamidoanilino)-6,7-dimethoxyquinazoline
02
Targets
AURKA (Aurora kinase A)AURKB (Aurora kinase B)Cyclin-dependent kinase 2-cyclin E/A complexCDK3 (Cyclin-dependent kinase 3)CDK4 (Cyclin-dependent kinase 4)Cyclin-dependent kinase 6–cyclin D1 complexFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)GSK3 (Glycogen synthase kinase 3 beta)JAK2 JH2 (Janus kinase 2 (JAK2) JH2 pseudokinase domain)TEK (Tie2)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)CDK1 (Cyclin-dependent kinase 1)CDK2 (Cyclin-dependent kinase 2)
Beyond the preview
Go deeper on JNJ-7706621.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-7706621.